Lung Cancer News and Research RSS Feed - Lung Cancer News and Research Twitter

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
Study shows association between traffic-related air pollution and dark spots on the skin

Study shows association between traffic-related air pollution and dark spots on the skin

A largescale study that included women from Germany and China has demonstrated a link between levels of traffic-related air pollution and air pollution-associated gases with the formation of dark spots on the skin, known as lentigenes. The most pronounced changes were observed on the cheeks of Asian women over the age of 50. [More]
VolitionRx initiates study to assess NuQ blood tests for detection of prostate cancer

VolitionRx initiates study to assess NuQ blood tests for detection of prostate cancer

VolitionRx Limited today announced that it has initiated a study to assess the feasibility of using the Company’s NuQ blood tests to detect prostate cancer. The study is in collaboration with the Surrey Cancer Research Institute of the University of Surrey in the UK. [More]
New method could help scientists conduct in-depth research on malignant tumors in cancer patients

New method could help scientists conduct in-depth research on malignant tumors in cancer patients

Scientists at the Children's Medical Center Research Institute at UT Southwestern have pioneered a new method for conducting in-depth research on malignant tumors in patients, in the process discovering new complexities underlying cancer biology and overturning a nearly century-old perception about cancer metabolism. [More]
AstraZeneca’s TAGRISSO (osimertinib) approved in EU for metastatic EGFR T790M mutation-positive NSCLC

AstraZeneca’s TAGRISSO (osimertinib) approved in EU for metastatic EGFR T790M mutation-positive NSCLC

AstraZeneca today announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). [More]
New drug cocktail may show promise in NSCLC patients

New drug cocktail may show promise in NSCLC patients

A drug approved by the Food and Drug Administration for melanoma in combination with a common cholesterol-lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai. [More]
Biochemical compound demonstrates increasing potential for use in cancer imaging

Biochemical compound demonstrates increasing potential for use in cancer imaging

In the paper, an international team reviewed studies conducted over the past 30 years on a particular tracer, called “18F-FLT,” and found that it has the potential to improve diagnostic imaging, and thus treatment, of some cancers. [More]
Frequent consumption of nuts may reduce risk of breast, colon, pancreatic and lung cancer

Frequent consumption of nuts may reduce risk of breast, colon, pancreatic and lung cancer

Adding nuts to your diet is associated to a reduction in the risk of cancer. This is the main conclusion of multiple studies that have shown that eating 2 or 3 servings per week (57-84 g) of nuts is associated to a reduction in the risk of some types of cancer (breast, colon, pancreatic and lung cancer). [More]

New patient-friendly website launched for people diagnosed with KRAS-mutant lung cancer

LUNGevity President Andrea Ferris, a member of the Stand Up to Cancer Lung Cancer Dream Team, presented the team's newly launched website, a patient-centric resource that enables users to be active, informed participants in their diagnosis and treatment, at a poster session at the 2016 Stand Up to Cancer (SU2C) Scientific Summit. [More]
Overall EU cancer, leukaemia mortality rates to fall in 2016

Overall EU cancer, leukaemia mortality rates to fall in 2016

Total cancer-related mortality rates for men and women in the European Union will decline in 2016, say researchers who predict falls in death rates from most neoplasms, including leukaemia. [More]
Mutation or amplification of HER2 gene may lead to lung cancer

Mutation or amplification of HER2 gene may lead to lung cancer

A joint study by University of Colorado Cancer Center and Memorial Sloan Kettering Cancer Center published in the Journal of Thoracic Oncology shows two distinct causes of HER2 activation in lung cancer: mutation of the gene and amplification of the gene. [More]
BMI affects outcomes following lung cancer surgery

BMI affects outcomes following lung cancer surgery

Body mass index (BMI) affects outcomes following lung resection (removal of part of the lung) for lung cancer. Patients with very high or very low BMIs (a measure of body mass based on height and weight) have the highest risks for complications, according to a scientific presentation at the 52nd Annual Meeting of The Society of Thoracic Surgeons. [More]
Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Quest Diagnostics to offer in vitro diagnostic test for use in detection of PD-L1 expression for melanoma

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced it will offer clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx qualitative test from Dako, an Agilent Technologies company. [More]
Halozyme closes $150 million royalty-backed debt transaction

Halozyme closes $150 million royalty-backed debt transaction

Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta. [More]
Researchers identify biomarkers that may influence potential new drug design or alternative treatments of cancer

Researchers identify biomarkers that may influence potential new drug design or alternative treatments of cancer

Researchers have discovered gene-targets (biomarkers) that may enable alternative treatments or the potential design of new drugs that target metastasis-promoting tumor genes. [More]
AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology. [More]
MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system's potential to fight cancer. [More]
OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. [More]
New imaging test detects prostate cancer much better than any other tests in use today

New imaging test detects prostate cancer much better than any other tests in use today

Researchers at Thomas Jefferson University have found the method they developed to image the prostate appears to be much better at detecting prostate cancer than any other test — radiographical, biopsy or blood — in use today. [More]
TG4010 vaccine promising in advanced NSCLC

TG4010 vaccine promising in advanced NSCLC

Addition of the TG4010 vaccine to first-line chemotherapy improves outcomes in patients with advanced non-small-cell lung cancer, show the results of a placebo controlled trial. [More]
Combination of PARP inhibitors and c-MET may benefit breast cancer patients

Combination of PARP inhibitors and c-MET may benefit breast cancer patients

Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed in many cancers. [More]
Advertisement